Biote — Third Quarter 2026 Earnings Summary

Biote reported third-quarter 2026 revenue of $43.3 million, representing a 9.6% decline from the prior year, driven by a 15.1% drop in procedure revenue. The company posted a net income of $0.6 million and an adjusted EBITDA of $5.1 million, with gross profit margins contracting to 67.7% due to the residual effects of a voluntary product recall. Despite the slower-than-anticipated return to growth, Biote maintained its full-year 2026 financial guidance, projecting revenue above $175 million and adjusted EBITDA above $25 million.